香港特区政府财政司司长陈茂波发文表示，随着港股市场近期回暖和新股集资活动活跃，韩国金融机构 对投资香港与内地市场兴趣浓厚。今年前五个月，韩国持牌机构在港证券交易额已超1.5万亿港元，是 去年全年的2.8倍。韩国投行也成为了多只在港上市新股的基石投资者。7月8日至10日，陈茂波率团在 韩国首尔进行三天访问，期间向当地金融、贸易、工商和科创界等推介香港最新发展和机遇。他在文中 提到，我国在科技创新领域不断取得突破，加上国家支持科创企业在港上市，让韩国投资界希望增加对 在香港及内地企业的资产配置比例。香港的金融产品创新也为港股市场吸引来了韩国的资金。(中证金 牛座) ...

【导读】年内 新成立 的ETF 数量 和规模均超去年全年 中国基金报记者 曹雯璟 今年以来， 无论是新成立的 ETF 产品数量还是发行规模均已超过2024年全年水平，从种类 来看，ETF发行呈现出多元化和细分化的特点。其中，股票型ETF在新发ETF中仍保持主导地 位，债券型ETF也加速密集新发，尤其聚焦在高等级信用债和科创债方面。 Wind数据显示，按基金成立日为统计口径， 截至7月11日， 今年以来， 已成立 的 ETF产品 达 184 只，募集 规模 达 1464.68亿元，无论是新成立的产品数量还是发行规模均已超过 2024年全年水平。 其中，股票型ETF 发行成立 164只，份额占比约65%，债券型ETF发行 成立 18只，份额占 比高达34.61%，跨境型ETF 发行成立 2只，份额仅占不足1%，而商品型ETF和货币型ETF 在2025年均尚未发行新产品。 值得关注的是， 年内债券型ETF也加速密集新发， 其中，科创债ETF 成为 绝对主力，目前 共发行10只科创债ETF，合计发行份额约290亿 份 ，占债券型ETF发行份额近57%。 在股票型ETF 方面 ，自由现金流ETF迎来密集发行高峰，目前已 ...

这只基金为全世界规模排名靠前的主动管理新兴市场基金。截至5月底，基金的前五大重仓股 为台积电、腾讯控股、华住集团、Kotak Mahindra Bank Ltd、美团等。5月，该基金减持了 腾讯控股和美团，减持幅度分别为5.31%和24.77%。在此期间，该基金还增持宁德时代 22.16%，增持阿里巴巴14.79%。前25大重仓股中，基金对恒瑞医药增持幅度最大。 该基金的时任基金经理Justin Leverenz 曾经撰文表示看好中国医药行业。 6月，Justin Leverenz撰文表示，过去五年，中国已从跟随者变成药物研发的先锋。中国跨 越传统化学药物和生物制药的研发阶段，直接跃入新型复杂治疗模式的前沿。 同一篇文章表示，目前，中国生物技术创新领域的领军企业包括传统生物技术或制药公司， 以及CRDMO（合同研发制造组织）公司。CRDMO企业与生物技术、生物制药公司在药物研 发和商业化的各个环节开展合作。中国企业在血液肿瘤治疗领域确立了全球临床和商业领先 地位。中国已成为全球制药和生物技术巨头寻求临床管线的重要市场。在向制药公司进行生 物技术对外授权的交易中，中国占比从2019—2020年的4%增至2023 ...

Group 1 - Invesco Developing Markets Fund increased its holdings in Jiangsu Hengrui Pharmaceuticals by 100% in May, with a total market value of HKD 185,661,247 [2][3] - The fund's total size is approximately USD 14.1 billion, equivalent to about CNY 101.24 billion [2] - The fund's top five holdings include TSMC, Tencent, Huazhu Group, Kotak Mahindra Bank, and Meituan, with reductions in Tencent and Meituan by 5.31% and 24.77% respectively [3] Group 2 - Justin Leverenz, the fund manager, expressed optimism about the Chinese pharmaceutical industry, noting China's transition to a leader in drug development [4] - China has established a significant position in the global clinical and commercial landscape for blood cancer treatment, with its share of biotech licensing transactions increasing from 4% in 2019-2020 to 12% in 2023-2024 [4] Group 3 - JPMorgan Asset Management increased its stake in Jiangsu Hengrui Pharmaceuticals by 18.49% in May [5] - Allianz Investment also raised its holdings in Jiangsu Hengrui Pharmaceuticals by 8.47% [7] Group 4 - Fidelity China Focus Fund and FSSA China Growth Fund have also shown interest in various Chinese companies, with Fidelity increasing its stake in Alibaba by 12.46% and in Trip.com by 9.41% [9][10] - Temasek Holdings reported a net asset value of USD 340 billion, with a focus on long-term prospects in China, which represents 18% of its portfolio [11]

Group 1 - The core viewpoint is that the Federal Reserve's monetary policy direction is crucial for asset prices, with increasing expectations for a shift to a loosening cycle due to limited inflation impact from recent tariff policies [1][2] Group 2 - Tariffs imposed by the U.S. government have had a limited effect on inflation, with the import price index showing no significant increase post-tariff, indicating that the cost burden is primarily on U.S. importers rather than consumers [2] - Core CPI and PPI remain stable, with core PPI growth at only 0.1% in May, contrasting sharply with the 10% tariffs, suggesting that inflationary pressures are easing [2] Group 3 - The current economic environment in the U.S. provides ample space for monetary policy easing, with actual interest rates significantly higher than core inflation rates, leading to expectations of rate cuts starting in September [3] - The market anticipates a gradual shift to a dovish stance from the Federal Reserve, with the federal funds rate potentially dropping to 3.75% by year-end [3] Group 4 - Trade policy impacts are expected to be limited, with recent agreements showing a compromise on tariffs, indicating a stable external environment for the bond market over the next few quarters [4] Group 5 - The ten-year Treasury ETF (511260) is highlighted as a key investment tool in the upcoming loosening cycle, effectively reflecting market trends and providing flexibility for investors [5] - The ETF is positioned to benefit from anticipated declines in ten-year Treasury yields as the market adjusts to expected rate cuts, supported by both policy and market dynamics [5]

当前美股市场正处于多重因素交织的关键节点：高盛上调标普500指数回报率预期、T 朗普政府关税政 策引发企业成本担忧、上市公司加密资产配置行为持续增加，这些动向不仅左右着美股短期走势，更与 加密货币市场形成显著联动。XBIT 作为连接传统金融与加密生态的去中心化交易平台，正通过技术特 性为投资者提供跨市场应对策略。 高盛上调标普预期，美股与加密资产联动性增强 币界网数据显示，高盛最新报告将标普500指数3个月、6个月和12 个月的预期回报率分别上调至+ 3%（6400 点）、+6%（6600 点）和 + 11%（6900 点），引发市场对美股新一轮上涨周期的讨论。值得 注意的是，这一预期调整与美国现货比特币 ETF 近期持续净流入形成呼应，显示机构资金在传统股市 与加密市场的配置平衡正在发生变化。 图片来源:币界网 XBIT 去中心化交易所平台数据显示，标普500成分股中持有加密资产的公司数量已达47家，较去年同 期增长38%。"美股上市公司的加密资产配置行为正在成为连接两个市场的关键纽带"，XBIT 分析师指 出，其平台上追踪美股与加密货币关联度的指标显示，近30天两者相关性系数升至0.62，为2023年以来 ...

Core Viewpoint - The People's Bank of China and the Hong Kong Monetary Authority announced three measures to optimize the Bond Connect program, particularly expanding the investor base for the "Southbound" channel to include more non-bank financial institutions [1] Group 1: Expansion of Investor Base - The "Southbound" channel will now allow securities firms, funds, insurance companies, and wealth management firms to participate, broadening the investment opportunities for domestic investors [1][2] - Currently, only 41 bank-type financial institutions and qualified domestic institutional investors (QDII and RQDII) can invest through the "Southbound" channel [1] Group 2: Benefits for Non-Bank Financial Institutions - The expansion provides non-bank institutions with a wider global asset allocation channel, enhancing flexibility and potential returns on investments [2] - Multi-currency and multi-market allocations will help mitigate the impact of interest rate fluctuations in a single market, thereby increasing risk resilience [2] - Non-bank institutions can dynamically adjust their domestic and foreign asset allocation ratios, leveraging differences in monetary policies across regions to alleviate operational pressures [2] Group 3: Market Impact and Future Outlook - The increase in market participants is expected to bring more incremental funds to the Hong Kong bond market, improving liquidity and trading scale [3] - As of May this year, the "Southbound" channel has facilitated the trading of 918 bonds with a balance of 532.94 billion yuan [3] - Future enhancements may include the introduction of derivatives like interest rate swaps and options to meet institutional hedging needs [3]

在港股和北交所等行情带动下，截至7月9日，年内主动权益基金大幅跑赢了被动指数基金。 其中，业绩最好的主动权益基金，年内收益率接近100%，与收益率最高的指数基金拉开了近34个百分点。无 论是单只产品业绩排名还是整体平均业绩对比，主动权益基金均呈现出了优于被动指数基金的投资优势。 基金 业 人士对券商中国记者分析称，这是基于医药等行情启动之下基金经理在选股上发挥出了主观能动性。 但这并不意味着被动指数基金没有投资优势。下半年的市场机会也并不局限于创新药，科技、红利、新消费等 领域都具备投资机会。 主动权益基金霸榜 根据Wind数据统计，截至7月9日，全市场权益型基金今年以来业绩排名前十（以初始基金为统计对象）的， 均为主动权益产品，以港股、医药、北交所这三类主题产品为主。 其中，汇添富香港优势精选A以98.16%的业绩排名第一。紧跟其后的是长城医药产业精选A(81.45%)、中信建 投北交所精选两年定开A（80.95%）、中银港股通医药A（77.14%）、永赢医药创新智选A（76.76%）。 排名第六到第十的，有重仓港股的广发成长领航一年持有A（76.37%），以及重仓医药 股 的华安医药生物A （75.44% ...

地方债扩容、创新品种崛起和跨境融资优化。 近期，中国债券市场呈现出多维度的发展态势。一方面，地方债规模持续扩大，截至5月末存量余额已 突破51万亿元，成为国内债券市场的第一大品种。与此同时，绿色债、科创债等新兴债券品类快速增 长，为经济高质量转型提供了重要支持。特别是科创债及债券科技板的推出，为市场注入了新的活力， 也为投资者带来了新的机遇。 另一方面，随着银行挂牌存款利率全面进入"1时代"，"存款搬家"现象越发显著，居民财富配置正从传 统存款转向银行理财、保险、基金等多元化金融产品。这一趋势在低利率、低波动的市场环境下尤为突 出，投资者对稳健、高性价比以及更高收益的投资策略需求日益增长。 从债券市场品类来看，地方债占据了庞大的规模。截至5月末，地方债存量余额已突破51万亿元，稳居 中国债券市场第一大品种的位置。地方债在促进发展、拉动内需等方面的作用日益显著。 中央国债登记结算有限责任公司上海总部副总经理王桂指出，今年中央政府已陆续下达全年地方债发行 额度。据初步估算，今年新增地方债供给将超过10万亿元。近年来，广东、深圳、海南等地纷纷赴港澳 地区面向境外投资者发行债券，全国36个地区也积极面向柜台市场发行债 ...

·········································································································[Table_Title] 研究报告 Research Report 7 Jul 2025 ```··························································································································································································································································· 东南亚可选消费必需消费 Southeast Asia Discretionary Staples 东南亚指数双周报第 2 期：区域市场企稳回升 Southeast Asia Index Tracking: Reg ...